Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fusion genes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Fusion genes. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-003582-28 Sponsor Protocol Number: LOXO-TRK-15002 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned) IE (Completed) ES (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) BE (Completed) CZ (Completed) SK (Completed) NO (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003498-16 Sponsor Protocol Number: LOXO-TRK-15003 Start Date*: 2017-02-10
    Sponsor Name:Loxo Oncology Inc.
    Full Title: A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
    Medical condition: Central Nervous System Neoplasms and advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007959 Central nervous system neoplasm NOS LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049516 Malignant tumor LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007958 Central nervous system neoplasm PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007960 Central nervous system neoplasms malignant NEC HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IE (Trial now transitioned) PL (Completed) IT (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002737-38 Sponsor Protocol Number: EUCROSS Start Date*: 2014-05-13
    Sponsor Name:University of Cologne
    Full Title: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations
    Medical condition: Adult patients with either firstly diagnosed or relapsed advanced adenocarcinoma of the lung harbouring ROS1 translocation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025032 Lung adenocarcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000126-38 Sponsor Protocol Number: OVG2012/05 Start Date*: 2014-04-08
    Sponsor Name:University of Oxford
    Full Title: Towards improved meningococcal vaccines: a randomised, descriptive, open label study exploring the relationship between gene expression signatures with reactogenicity and immunogenicity following v...
    Medical condition: This study aims to investigate gene expression following vaccination with 4CMenB and relate this to vaccine reactions and to immune response
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002124-17 Sponsor Protocol Number: IMO-AFLI-2013-01 Start Date*: 2013-10-04
    Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular
    Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD).
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003277-42 Sponsor Protocol Number: MCLA-128-CL01 Start Date*: 2015-01-13
    Sponsor Name:Merus B.V.
    Full Title: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Ongoing) FR (Trial now transitioned) PT (Completed) NO (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002047-24 Sponsor Protocol Number: SAKK56/07 Start Date*: 2008-04-29
    Sponsor Name:Swiss Group for Clinical Cancer Reaserch (SAKK)
    Full Title: Trial SAKK 56/07 Dasatinib first-line treatment in gastrointestinal stromal tumors. A multicenter phase II trial.
    Medical condition: GIST (Gastrointestinal stromal tumor) is a rare disease affecting 15 patients per 1 million individuals and comprising 5% of all sarcomas. Mutations in the genes of KIT or PDGFRA lead to constituti...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002094-18 Sponsor Protocol Number: REL-AML001/2017 Start Date*: 2018-05-18
    Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA
    Full Title: Prospective evaluation of a continuation therapy with Midostaurin in adult patients with core-binding factor leukemia and integrated genetic analysis: a multi-center phase II study
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003863-23 Sponsor Protocol Number: TUD-MOSAIC-075 Start Date*: 2020-07-03
    Sponsor Name:Technische Universität Dresden
    Full Title: Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia
    Medical condition: Patients with newly diagnosed acute myeloid leukemia (AML) fit for intensive curative treatment displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FL...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002259-14 Sponsor Protocol Number: TRG12-05 Start Date*: 2013-11-27
    Sponsor Name:University of Oxford
    Full Title: The effect of lixisenatide in type 1 diabetes
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002228-25 Sponsor Protocol Number: D2615C00001 Start Date*: 2015-11-10
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY)
    Medical condition: Muscle-invasive bladder cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-002798-80 Sponsor Protocol Number: IM101-332 Start Date*: 2013-08-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GR (Completed) IT (Completed) CZ (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002549-39 Sponsor Protocol Number: Ponatinib-1501 Start Date*: 2020-12-07
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho...
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) NL (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004050-16 Sponsor Protocol Number: HEAT-AML Start Date*: 2019-08-01
    Sponsor Name:University Hospital Karolinska
    Full Title: HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A phase I/II multicenter study to assess the tolerability and efficacy of the addition of hydroxyurea to standard a...
    Medical condition: Newly diagnosed acute myeloid leukaemia (AML) in patients ≥ 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10024291 Leukaemias acute myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001535-87 Sponsor Protocol Number: BLU-263-2101 Start Date*: 2023-02-03
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies
    Medical condition: Advanced Systemic Mastocytosis (AdvSM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042949 Systemic mastocytosis PT
    26.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056453 Aggressive systemic mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002934-35 Sponsor Protocol Number: 2.1 Start Date*: 2013-01-22
    Sponsor Name:Västra Götaland Regionen
    Full Title: NOPHO-DBH AML 2012 Protocol Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years
    Medical condition: Acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001319-36 Sponsor Protocol Number: FIERCE-21(B-701-U21) Start Date*: 2017-08-23
    Sponsor Name:BioClin Therapeutics, Inc.
    Full Title: A Dose Escalation, Expansion Study of Vofatamab (B 701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After,...
    Medical condition: Treatment of progressed or refractory metastatic UCC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001982-26 Sponsor Protocol Number: OZM-063 Start Date*: 2018-04-26
    Sponsor Name:The Hospital for Sick Children
    Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma...
    Medical condition: Unresectable or progressive low grade glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000392-33 Sponsor Protocol Number: AML1718 Start Date*: 2018-08-29
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: A Safety Run-in and phase II, open-label, multicentre, study investigating safety, tolerability and effectiveness of Venetoclax add in combination at Fludarabine, Cytarabine and Idarubicine in ind...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002752-27 Sponsor Protocol Number: NCT-2014-0235/N2M2 Start Date*: 2018-04-04
    Sponsor Name:University Hospital Heidelberg
    Full Title: Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Maste...
    Medical condition: Patient with newly diagnosed glioblastoma with unmethylated MGMT promoter
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:22:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA